Roche’s Giredestrant Leads the Way as First Oral SERD to Improve Outcomes in Early Breast Cancer | iPharmaCenter

Roche recently disclosed promising findings from the phase III lidERA Breast Cancer trial, where their experimental oral drug, giredestrant, showed a significant improvement in invasive disease-free survival compared to standard endocrine therapies.

This study involved over 4,100 patients diagnosed with early-stage breast cancer characterized by oestrogen receptor-positive (ER+), HER2-negative tumors. The trial’s interim analysis revealed that giredestrant not only met but surpassed its primary goal with clear statistical significance and clinical relevance, marking the first oral selective estrogen receptor degrader (SERD) to achieve such results in this adjuvant setting.

These groundbreaking outcomes position giredestrant as a promising candidate to become the new standard endocrine treatment for early-stage breast cancer, where there remains a real chance for cure. While data on overall survival remain immature, a positive trend was noted. Additionally, giredestrant was generally well tolerated, with a safety profile consistent with previous observations and no unforeseen adverse effects reported.

ER-positive breast cancer accounts for roughly 70% of all breast cancer diagnoses. Despite existing therapies, up to one-third of patients experience recurrence after adjuvant endocrine treatments, and many discontinue therapy prematurely due to side effects, increasing their mortality risk. This underscores the urgent need for more effective, tolerable therapies that enhance patient adherence and delay or prevent disease return.

The lidERA results build on prior positive phase III data from the evERA Breast Cancer study and earlier neoadjuvant trials like coopERA, which indicated giredestrant’s superiority over aromatase inhibitors in suppressing tumor cell proliferation. Roche’s ongoing extensive clinical development program for giredestrant spans multiple stages and treatment lines, aiming to offer improved outcomes to patients with ER-positive breast cancer across both early and advanced disease stages.

The lidERA study is a randomized, open-label, multinational trial evaluating giredestrant versus standard endocrine therapy in patients with medium- to high-risk early breast cancer, focusing on invasive disease-free survival as the primary endpoint, excluding unrelated non-breast cancers. Secondary endpoints include overall survival, disease-free survival, and safety assessments.

Giredestrant works as a powerful, next-generation oral selective estrogen receptor degrader and complete antagonist by preventing estrogen from engaging its receptor, triggering receptor breakdown, and thereby inhibiting cancer cell growth.

Roche plans to present these findings at upcoming medical conferences and submit data to regulatory authorities globally, aiming to make this promising therapy accessible to patients worldwide.

This breakthrough reinforces giredestrant’s potential to transform the treatment landscape in ER-positive early breast cancer with a more effective and better tolerated oral endocrine therapy option.